GlycoMimetics Inc (GLYC)
0.3168
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 16:00
0.3133
0.00 (0.00%)
Pre-Market: 20:00
GlycoMimetics Cash from Operations (Quarterly): -7.994M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -7.994M |
| June 30, 2024 | -8.893M |
| March 31, 2024 | -10.51M |
| December 31, 2023 | -7.615M |
| September 30, 2023 | -8.683M |
| June 30, 2023 | -6.975M |
| March 31, 2023 | -11.61M |
| December 31, 2022 | -7.912M |
| September 30, 2022 | -8.617M |
| June 30, 2022 | -16.23M |
| March 31, 2022 | -13.70M |
| December 31, 2021 | -12.81M |
| September 30, 2021 | -16.95M |
| June 30, 2021 | -13.61M |
| March 31, 2021 | -14.13M |
| December 31, 2020 | -9.686M |
| September 30, 2020 | -11.50M |
| June 30, 2020 | -14.55M |
| March 31, 2020 | -3.500M |
| December 31, 2019 | -12.79M |
| September 30, 2019 | -13.45M |
| June 30, 2019 | -11.39M |
| March 31, 2019 | -14.35M |
| December 31, 2018 | -9.98M |
| Date | Value |
|---|---|
| September 30, 2018 | -10.08M |
| June 30, 2018 | -13.06M |
| March 31, 2018 | -10.21M |
| December 31, 2017 | -8.369M |
| September 30, 2017 | -6.230M |
| June 30, 2017 | -6.108M |
| March 31, 2017 | -9.062M |
| December 31, 2016 | -5.955M |
| September 30, 2016 | -7.472M |
| June 30, 2016 | -7.075M |
| March 31, 2016 | -9.230M |
| December 31, 2015 | -6.958M |
| September 30, 2015 | 13.56M |
| June 30, 2015 | -6.143M |
| March 31, 2015 | -8.705M |
| December 31, 2014 | -6.154M |
| September 30, 2014 | -4.754M |
| June 30, 2014 | 9.214M |
| March 31, 2014 | -2.587M |
| December 31, 2013 | -5.566M |
| September 30, 2013 | -3.389M |
| June 30, 2013 | -2.708M |
| March 31, 2013 | -3.876M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-16.95M
Minimum
Sep 2021
-3.500M
Maximum
Mar 2020
-10.91M
Average
-11.01M
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Arbutus Biopharma Corp | -20.74M |
| Revance Therapeutics Inc | -41.09M |
| FibroGen Inc | -8.376M |
| Cidara Therapeutics Inc | -36.70M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -35.02M |
| Free Cash Flow Per Share (Quarterly) | -0.124 |
| Free Cash Flow Yield | -171.5% |